Proactive Investors - Run By Investors For Investors

Summit Therapeutics discovers new antibiotic compounds in fight against gonorrhoea

The AIM-listed biopharma company said that in early testing, the new compounds had been shown to have high potency against strains of gonorrhoea with no development of resistance to date
Man using microscope
Summit intends to select a candidate for Investigational New Drug enabling studies in the second half of 2018

Summit Therapeutics PLC (LON:SUMM) shares jumped almost 7% higher on Tuesday after the biopharma firm said its Infectious Diseases Technology Platform has discovered a series of antibiotic compounds that kill gonorrhoea bacteria.

The AIM-listed company said that in early testing the new compounds had been shown to have high potency against strains of gonorrhoea with no development of resistance to date.

READ: Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial

The firm added that it intended to select a candidate from the programme for Investigational New Drug (IND) enabling studies in the second half of 2018.

Dr David Roblin, president of R&D at Summit, said: "Without truly novel mechanism antibacterial drugs we cannot address the issue of antimicrobial resistance. Nowhere is this need more obvious than in gonorrhoea, where increasing resistance and a lack of innovation means we are now nearing an era of untreatable disease."

"Tackling this disease therefore fits squarely within Summit's strategic vision: the development of new mechanism therapies designed to treat specific diseases. This approach aims to demonstrate clear advantages over existing standards of care combined with a compelling value proposition for patients, payors and healthcare providers", he added.

In afternoon trading, Summit Therapeutics' shares were 6.7% higher at 200p.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use